Arphra
live
S&P 5007,512.99-0.55%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.41+1.30%
US10Y4.43-0.92%
EUR/USD1.1615+0.20%
GOLD4,355.5+0.47%
WTI75.90-6.78%
BTC65,667.9-0.74%
S&P 5007,512.99-0.55%
NASDAQ29,968.13-1.89%
DOW51,999.67+0.64%
VIX16.41+1.30%
US10Y4.43-0.92%
EUR/USD1.1615+0.20%
GOLD4,355.5+0.47%
WTI75.90-6.78%
BTC65,667.9-0.74%

ANIP

ANI Pharmaceuticals, Inc.
HealthcareDrug Manufacturers - Specialty & GenericUSUSDPeers →
$82.59
LiveJun 16, 2026
AI Brief
Market cap
$1.88B
52w range
62.61 – 99.50
P / E
EPS · FY 2025
$3.32
Volume
61.83K
Revenue · FY 2025
$883.37M
+43.78% YoY

Explain this page

Arphra AI
Business description
· company · SEC profile

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.

Founded
IPO
May 05, 2000
Employees
897
HQ
Baudette, MN
CEO
Nikhil Lalwani
CFO
Exchange
NASDAQ
Fiscal year
Identifiers
· company_identifiers
CIK0001023024
CUSIP00182C103
ISINUS00182C1036
FIGIANIP US
LEI